Diagnosis and treatment in metastatic adenocarcinoma of unknown primary tumour.
作者信息
Taal B G, Veenhof C H, Blijham G H, Neijt J P
出版信息
Neth J Med. 1988 Apr;32(3-4):204-11.
PMID:3283582
Abstract
摘要
相似文献
1
Diagnosis and treatment in metastatic adenocarcinoma of unknown primary tumour.原发灶不明的转移性腺癌的诊断与治疗
Neth J Med. 1988 Apr;32(3-4):204-11.
2
Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin.联合化疗治疗原发灶不明的腺癌
Cancer Treat Rep. 1987 Jun;71(6):605-7.
3
[Cytostatic treatment of metastatic adenocarcinoma and anaplastic carcinoma of unknown primary origin].
Ugeskr Laeger. 1987 Jan 5;149(2):80-1.
4
Multiple nodules on the face and trunk in metastatic adenocarcinoma of unknown primary origin.多发面部和躯干结节，源于不明原发灶的转移性腺癌。
Singapore Med J. 2011 Jul;52(7):e163-6.
5
Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
Semin Oncol. 1994 Oct;21(5 Suppl 12):77-82.
6
Diagnostic and prognostic yield of tumor markers in cancer of unknown primary site.肿瘤标志物在原发部位不明癌症中的诊断及预后价值
J Coll Physicians Surg Pak. 2006 Feb;16(2):154-6.
7
[A successful combination therapy with resection and infusion chemotherapy for a patient with metastases from cancer of unknown origin].
Gan To Kagaku Ryoho. 2003 Mar;30(3):423-6.
8
[The CUP syndrome--malignant disease with unknown primary tumor. Part 4: Therapy and prognosis].[杯状综合征——原发肿瘤不明的恶性疾病。第4部分：治疗与预后]
Fortschr Med. 1992 Nov 10;110(31):587-8.
9
[The chemotherapy of metastases of unknown origin].
Lik Sprava. 1996 Jan-Feb(1-2):45-52.
10
Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.III类β微管蛋白是原发部位不明的癌中紫杉醇耐药的标志物。
Cancer Chemother Pharmacol. 2007 Jun;60(1):27-34. doi: 10.1007/s00280-006-0343-1. Epub 2006 Sep 22.
Zotero 插件